Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Future Innovations in Oncology: Early Stage Outlook [2018]

Product Code:
Publication Date:
July 2018

How is the Oncology treatment landscape expected to evolve over the next 10 years?

Oncology treatment has undergone a dramatic shift over the past 20 years with many drugs entering the space greatly improving survival outcomes and raising the standard of care for patients. PD-1/PD-L1 checkpoint inhibitors and CAR-T cell therapies represent key breakthroughs of the past decade. Find out what innovative approaches are coming next in this fast-evolving landscape and how cancer treatment is likely evolve in the long-term. Eight of the world’s leading key opinion leaders (KOLs) from the US and Europe provide their views on exciting therapy classes and the opportunities and challenges that face these strategies across multiple cancer settings.

Learn how KOLs see the future Oncology market evolving in Early Stage Outlook: Future Innovations In Oncology. Experts provide their candid views on novel therapies such as bispecific antibodies, checkpoint modulators, CAR-T cell therapies, next-generation cytokines amongst many other novel therapy classes.

Download sample pages

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Top takeaways

  • What does the future hold for bispecific antibodies and antibody-drug conjugates (ADCs)?  How do KOLs view these specific tumour-targeting strategies and can they forge a role in both haematological cancers and solid tumours?
  • Which novel checkpoint modulators are KOLs most optimistic about and why? LAG-3, TIM-3, IDO, OX40, GITR, CD40, 4-1BB modulators all form part of the early-stage pipeline; find out which of these novel mechanisms excite KOLs the most.
  • Does CAR-T cell therapy have applicability in solid tumours? The anti-CD19 CAR-T therapies have revolutionised the treatment of blood cancers.Find out what specific opportunities and challenges face these exciting treatments in solid tumours.
  • Is there any remaining opportunity for vaccine-based approaches in oncology? Despite all the past setbacks, what are KOLs’ current viewpoints on personalised vaccination strategies in cancer, and which ones are they most optimistic about?
  • How do experts view other novel therapy classes such as oncolytic virus therapies, next-generation cytokines and innate immune agonists? Find outwhich approaches may become part of future treatment.
  • Which other next-generation approaches fuel KOL excitement? Neoantigen-based approaches, other adoptive T-cell therapies and combination strategies are also in the early-stage pipeline. Which strategy do KOLs think offers the most promise and why? 
  • Combinations, biomarkers and tackling cancer resistance; what needs to be prioritised? What do companies need to focus on in terms of harnessing immunogenicity, overcoming cancer resistance and identifying appropriate patients for treatment?
  • How will innovative therapies shape future cancer treatment in the long-term?  Can any of the novel therapy classes secure a place in the treatment paradigm?
Request sample pages

Back to the top


“We will see more drugs coming and more tumours being treated over the next few years; very convinced about that. Now it's more the issue that the easy targets have been reached. It's getting more challenging to overcome the resistance or prevent resistance to prolong the duration of response.”
US Key Opinion Leader

“I think the immune-checkpoints [will become] a backbone. I'm not quite sure that PD-1/PD-L1 is necessarily the only backbone. For some tumours, maybe LAG-3 will be an even better backbone.”
US Key Opinion Leader

Therapy classes covered in the report

  • Bispecific antibodies (BiTEs and other bifunctional antibody approaches)
  • Antibody-drug conjugates (ADCs) and Immunotoxins
  • Immune checkpoint modulators
  • Adoptive T-cell therapies (CAR-T, TCR-T and TILs)
  • Oncolytic virus therapies
  • Vaccine-based approaches
  • Next-generation cytokine therapies
  • Innate immune agonists
  • Other targeted treatments

KOLs interviewed

KOLs from North America

  • Dr. Saad Khan MD; Medical oncologist and Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center, Dallas, Texas
  • Dr. Reshma Mahtani DO; Assistant Professor, Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida
  • Dr. Michael Morse MD; Professor of Medicine, Professor in the Department of Surgery, Duke University School of Medicine, Durham, North Carolina
  • Dr. Patrick Ott MD PhD; Assistant Professor of Medicine, Harvard Medical School, Clinical Director, Center for Immuno-Oncology and Melanoma, Dana-Farber Cancer Institute, Boston
  • Dr. Lei Zheng MD PhD; Associate Professor of Oncology, John Hopkins University, Baltimore, Maryland

KOLs from Europe

  • Professor Justin Stebbing MD MA FRCP FRCPath PhD; Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College and Imperial College Healthcare NHS Trust, London, UK
  • Anonymous German KOL. Professor and world-leading expert in Melanoma at a Leading Research Institute in Germany
  • Anonymous German KOL. Professor and leading expert in treatment of Haematological cancers at a Leading Cancer Institute in Germany. Expert in novel monoclonal antibody and antibody-drug conjugate approaches

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.


All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved